Johnson & Johnson (JNJ) Tax Provisions (2009 - 2026)
Johnson & Johnson (JNJ) posted Tax Provisions of $755.0 million for Q1 2026, up 603.33% sequentially from -$150.0 million in Q4 2025, and down 71.31% YoY from $2.6 billion in Q1 2025.
Johnson & Johnson (JNJ) Tax Provisions (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Tax Provisions data on file, last reported at $755.0 million in Q1 2026.
- Quarterly Tax Provisions fell 71.31% year-over-year to $755.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 billion (down 18.65% YoY) and the FY2025 annual result came in at $5.8 billion, up 120.41% from the prior year.
- Tax Provisions advanced to $755.0 million in Q1 2026 per JNJ's latest filing, from -$150.0 million in the prior quarter.
- The five-year high for Tax Provisions was $2.6 billion in Q1 2025, with the low at -$796.0 million in Q2 2023.
- Average Tax Provisions over 5 years is $863.6 million, with a median of $862.0 million recorded in 2022.
- Year-over-year, Tax Provisions sank 211.64% in 2023 and soared 473.42% in 2025.
- Johnson & Johnson's Tax Provisions stood at $862.0 million in 2022, then fell by 19.49% to $694.0 million in 2023, then tumbled by 34.29% to $456.0 million in 2024, then slumped by 132.89% to -$150.0 million in 2025, then soared by 603.33% to $755.0 million in 2026.
- Business Quant data shows JNJ's Tax Provisions at $755.0 million in Q1 2026, -$150.0 million in Q4 2025, and $2.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 1.45 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 755.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 342.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 3.08 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 709.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 265.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 559.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 461.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -683.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 58.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 755.00 Mn |
| Dec 28, 2025 | -150.00 Mn |
| Sep 28, 2025 | 2.34 Bn |
| Jun 29, 2025 | 954.00 Mn |
| Mar 30, 2025 | 2.63 Bn |
| Dec 29, 2024 | 456.00 Mn |
| Sep 29, 2024 | 644.00 Mn |
| Jun 30, 2024 | 1.06 Bn |
| Mar 31, 2024 | 459.00 Mn |
| Dec 31, 2023 | 694.00 Mn |
| Oct 1, 2023 | 908.00 Mn |
| Jul 2, 2023 | 930.00 Mn |
| Apr 2, 2023 | -796.00 Mn |
| Jan 1, 2023 | 1.19 Bn |
| Oct 2, 2022 | 862.00 Mn |
| Jul 3, 2022 | 1.03 Bn |
| Apr 3, 2022 | 713.00 Mn |
| Oct 3, 2021 | 182.00 Mn |
| Jul 4, 2021 | 384.00 Mn |
| Apr 4, 2021 | 1.23 Bn |